ANeuroTech gets positive feedback from US FDA for pivotal phase IIIb development programme for ANT-01 as an adjunctive anti depression drug for MDD

ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, announces that following a successful pre-IND meeting, the US Food and Drug Administration (FDA) has given positive feedback on its pivotal phase IIIb development programme of ANT-01 as an adjunctive anti-depression drug for major depressive disorder (MDD). The phase IIIb will include a secondary endpoint of improvement in cognitive function and the ability to feel pleasure, the first time this has been included in an anti-depression drug clinical trial. ANeuroTech will file for IND in Q4 2022 and apply for FDA Fast-Track Designation at the same time. More than 60% of people with depression and associated cognitive problems are not helped by initial treatments or experience challenging side-effects. ANeuroTech is developing ANT-01 as an adjunctive anti-depression drug with minimal or no side-effects. ANT-01 is a low dose of an existing drug substance, pipamperone dihydrochloride, a typical antipsychotic developed by the late Dr Paul Janssen (Founder of Janssen Pharmaceutica which merged with Johnson & Johnson) and marketed for over 40 years in Europe at a high dose range for the treatment of psychotic disorders. Dr Erik Buntinx, CEO and founder of ANeuroTech, discovered through his clinical practice that ANT-01 has a unique high selectivity and affinity for the serotonin 5-HT2A and dopamine D4DR brain receptors, and shows potential as an adjunctive treatment with fewer side effects. The pivotal phase IIIb development programme will assess the safety and efficacy of a single low (15mg) dose of ANT-01 combined with a first-line antidepressant versus placebo, in MDD patients with insufficient response to selective serotonin re-uptake inhibitor (SSRI) or selective noradrenaline serotonin re-uptake inhibitor (SNRI) treatment. The phase IIIb follows positive clinical data generated from earlier trials which demonstrated superior antidepressant activity of ANT-01 with a favourable safety profile. The data also showed an improvement in the ability to feel pleasure and in cognitive function, which has not been demonstrated by any other antidepressant molecule. This will be further explored in the phase IIIb programme, which will recruit 300 patients at a number of US sites and is planned to begin in 2023. ANeuroTech also announces that seasoned biotech entrepreneur, Dr Rudi Pauwels, has joined the Board of directors as executive chairman. Rudi has over 30 years

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!